Summary of Study ST003984

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002493. The data can be accessed directly via it's Project DOI: 10.21228/M8D54V This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003984
Study TitleMetabolome analysis as a potential source of endometriosis biomarkers with the use of multiomics approach in its diagnosis
Study SummaryThis study aimed to analyse the metabolomic profiles of plasma and peritoneal fluid samples obtained from women with endometriosis compared to controls. Our multicenter study involved sample collection from women undergoing laparoscopic surgery. The metabolomic profiles of plasma samples obtained from 73 women with endometriosis and 35 controls and peritoneal fluid (PF) samples from 53 women with endometriosis and 34 controls were analysed using mass spectrometry techniques. Statistical testing identified five lipids in PF and one in plasma, exhibiting significant differences between the endometriosis and control groups. Importantly, phosphatidylcholine (PC ae C30:2) level was consistently increased in both sample sources. Additional chemometric PLS-DA analyses identified a set of 20 metabolites present in PF and 26 compounds in plasma, which differentiate women with endometriosis and the control group among samples collected during the luteal phase of the menstrual cycle (AUC equal to 0.84 in PF and 0.95 in plasma). We also used a simple approach to build a classification model based on the sets of metabolites in combination with autoantibodies selected using protein microarrays from our previous study. The classification performance obtained on the joined metabolomic and proteomic feature sets exceeds that achievable for separate assays.
Institute
Calisia University
DepartmentWomen’s Health Research Institute
Last NameWojtyła
First NameCezary
AddressNowy Świat 4, 62-800 Kalisz, Poland
Emailc.wojtyla@uniwersytetkaliski.edu.pl
Phone+48 62 76 79 500
Submit Date2025-05-29
Raw Data AvailableYes
Raw Data File Type(s)mzML, raw(Waters)
Analysis Type DetailFIA-MS/LC-MS
Release Date2025-07-09
Release Version1
Cezary Wojtyła Cezary Wojtyła
https://dx.doi.org/10.21228/M8D54V
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002493
Project DOI:doi: 10.21228/M8D54V
Project Title:Metabolome analysis as a potential source of endometriosis biomarkers
Project Summary:This project aims to analyse the metabolomic profiles of plasma and peritoneal fluid samples obtained from women with endometriosis and compare them to those of the control group. It involves the collection of samples from women undergoing laparoscopic surgery in several medical centres.
Institute:Calisia University
Department:Women’s Health Research Institute
Last Name:Wojtyła
First Name:Cezary
Address:Nowy Świat 4, 62-800 Kalisz, Poland
Email:c.wojtyla@uniwersytetkaliski.edu.pl
Phone:+48 62 76 79 500

Subject:

Subject ID:SU004121
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Group Stage Cycle phase
SA4544511044480715Peritoneal fluid Control C Luteal
SA4544521044480666Peritoneal fluid Control C Luteal
SA4544531044481918Peritoneal fluid Control C Luteal
SA4544541044480772Peritoneal fluid Control C Luteal
SA4544551044480768Peritoneal fluid Control C Luteal
SA4544561044481922Peritoneal fluid Control C Luteal
SA4544571044480628Peritoneal fluid Control C Luteal
SA4544581044480753Peritoneal fluid Control C Luteal
SA4544591044481961Peritoneal fluid Control C Luteal
SA4544601044480734Peritoneal fluid Control C Luteal
SA4544611044481903Peritoneal fluid Control C Proliferative
SA4544621044481937Peritoneal fluid Control C Proliferative
SA4544631044481941Peritoneal fluid Control C Proliferative
SA4544641044481956Peritoneal fluid Control C Proliferative
SA4544651044480690Peritoneal fluid Control C Proliferative
SA4544661044480583Peritoneal fluid Control C Proliferative
SA4544671044480720Peritoneal fluid Control C Proliferative
SA4544681044480701Peritoneal fluid Control C Proliferative
SA4544691044481888Peritoneal fluid Control C Proliferative
SA4544701044480598Peritoneal fluid Control C Proliferative
SA4544711044480609Peritoneal fluid Control C Proliferative
SA4544721044480613Peritoneal fluid Control C Proliferative
SA4544731044480632Peritoneal fluid Control C Proliferative
SA4544741044480647Peritoneal fluid Control C Proliferative
SA4544751044480651Peritoneal fluid Control C Proliferative
SA4544761044480671Peritoneal fluid Control C Proliferative
SA4544771044481892Peritoneal fluid Control C Proliferative
SA4544781044480685Peritoneal fluid Control C Proliferative
SA4544791044481873Peritoneal fluid Control C Proliferative
SA4544801044481854Peritoneal fluid Control C Proliferative
SA4544811044481840Peritoneal fluid Control C Proliferative
SA4544821044481835Peritoneal fluid Control C Proliferative
SA4544831044480787Peritoneal fluid Control C Proliferative
SA4544841044480749Peritoneal fluid Control C Proliferative
SA4544851044481869Peritoneal fluid Control C Proliferative
SA4545261044481670Peritoneal fluid Endometriosis I Luteal
SA4545271044481631Peritoneal fluid Endometriosis I Luteal
SA4545281044481419Peritoneal fluid Endometriosis I Proliferative
SA4545291044481404Peritoneal fluid Endometriosis I Proliferative
SA4545301044481699Peritoneal fluid Endometriosis I Proliferative
SA4545311044481461Peritoneal fluid Endometriosis I Proliferative
SA4545321044481423Peritoneal fluid Endometriosis I Proliferative
SA4545331044481438Peritoneal fluid Endometriosis I Proliferative
SA4545341044481457Peritoneal fluid Endometriosis I Proliferative
SA4545351044481627Peritoneal fluid Endometriosis I Proliferative
SA4545361044481511Peritoneal fluid Endometriosis I Proliferative
SA4545371044482011Peritoneal fluid Endometriosis I Proliferative
SA4545381044481786Peritoneal fluid Endometriosis I Proliferative
SA4545391044481544Peritoneal fluid Endometriosis I Proliferative
SA4545111044481646Peritoneal fluid Endometriosis II Luteal
SA4545121044481665Peritoneal fluid Endometriosis II Luteal
SA4545131044482059Peritoneal fluid Endometriosis II Proliferative
SA4545141044481442Peritoneal fluid Endometriosis II Proliferative
SA4545151044482006Peritoneal fluid Endometriosis II Proliferative
SA4545161044480564Peritoneal fluid Endometriosis II Proliferative
SA4545171044481748Peritoneal fluid Endometriosis II Proliferative
SA4545181044481612Peritoneal fluid Endometriosis II Proliferative
SA4544861044481729Peritoneal fluid Endometriosis III Luteal
SA4544871044481767Peritoneal fluid Endometriosis III Luteal
SA4544881044481530Peritoneal fluid Endometriosis III Luteal
SA4544891044481684Peritoneal fluid Endometriosis III Luteal
SA4544901044481700Peritoneal fluid Endometriosis III Luteal
SA4544911044481771Peritoneal fluid Endometriosis III Luteal
SA4544921044481506Peritoneal fluid Endometriosis III Luteal
SA4544931044481791Peritoneal fluid Endometriosis III Luteal
SA4544941044481476Peritoneal fluid Endometriosis III Luteal
SA4544951044481821Peritoneal fluid Endometriosis III Luteal
SA4544961044481752Peritoneal fluid Endometriosis III Luteal
SA4544971044481714Peritoneal fluid Endometriosis III Proliferative
SA4544981044480579Peritoneal fluid Endometriosis III Proliferative
SA4544991044481481Peritoneal fluid Endometriosis III Proliferative
SA4545001044481651Peritoneal fluid Endometriosis III Proliferative
SA4545011044481597Peritoneal fluid Endometriosis III Proliferative
SA4545021044481578Peritoneal fluid Endometriosis III Proliferative
SA4545031044481563Peritoneal fluid Endometriosis III Proliferative
SA4545041044481816Peritoneal fluid Endometriosis III Proliferative
SA4545051044481559Peritoneal fluid Endometriosis III Proliferative
SA4545061044481801Peritoneal fluid Endometriosis III Proliferative
SA4545071044481525Peritoneal fluid Endometriosis III Proliferative
SA4545081044481994Peritoneal fluid Endometriosis III Proliferative
SA4545091044482078Peritoneal fluid Endometriosis III Proliferative
SA4545101044482044Peritoneal fluid Endometriosis III Proliferative
SA4545191044481582Peritoneal fluid Endometriosis IV Luteal
SA4545201044481733Peritoneal fluid Endometriosis IV Luteal
SA4545211044482030Peritoneal fluid Endometriosis IV Luteal
SA4545221044482025Peritoneal fluid Endometriosis IV Luteal
SA4545231044481495Peritoneal fluid Endometriosis IV Luteal
SA4545241044481608Peritoneal fluid Endometriosis IV Proliferative
SA4545251044482063Peritoneal fluid Endometriosis IV Proliferative
SA4545401044482170Plasma Control C Luteal
SA4545411044482082Plasma Control C Luteal
SA4545421044481064Plasma Control C Luteal
SA4545431044482127Plasma Control C Luteal
SA4545441044483368Plasma Control C Luteal
SA4545451044482199Plasma Control C Luteal
SA4545461044482214Plasma Control C Luteal
SA4545471044482229Plasma Control C Luteal
SA4545481044482233Plasma Control C Luteal
SA4545491044483320Plasma Control C Luteal
SA4545501044483349Plasma Control C Proliferative
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 197

Collection:

Collection ID:CO004114
Collection Summary:Peritoneal fluid was collected through aspiration using a Veress needle under direct visualisation immediately upon introduction of the laparoscope to avoid contamination with blood. The procedure was meticulously performed in line with the standard operating procedures of the Endometriosis Phenome and Biobanking Harmonisation Project. The collected peritoneal fluid was centrifuged at 1,000 × g for 10 min at 4 °C. The supernatant was transferred to a fresh 10 mL tube (Sarstedt) and divided into 500 µL tubes. Blood samples were collected before laparoscopy (before anaesthesia) in ethylenediaminetetraacetic acid (EDTA) 10 mL tubes (Sarstedt). The time lapse between sample collection (both plasma and peritoneal fluid) and processing was < 45 min. Blood samples were centrifuged at 2,500 × g for 10 min at 4 °C. Then, the plasma samples were split into 500 μL aliquots. Both materials were stored at -80 °C until further use.
Collection Protocol Filename:Endometriosis_methods.pdf
Sample Type:Plasma and Peritoneal fluid
Storage Conditions:-80℃

Treatment:

Treatment ID:TR004130
Treatment Summary:Biological material (plasma and peritoneal fluid) was obtained from women undergoing laparoscopic surgery for the following reasons: ovarian cyst, pelvic pain and/or infertility. The exclusion criteria were as follows: age under 18 and over 45 years old, irregular menstruation (< 25 or > 35 days), any form of hormonal therapy during the last three months before surgery, pelvic inflammatory disease, uterine fibroids, polycystic ovary syndrome, any autoimmune diseases and malignant or suspected malignant. The details of the study are described elsewhere [6]. The cycle phase was calculated from the last menstrual period and average length of the menstrual cycle. Women from the endometriosis group were diagnosed through laparoscopic findings, and each case was histopathologically confirmed. As controls, we recruited patients without visible endometriosis during laparoscopy. In this study we analysed plasma samples obtained from 73 women with endometriosis and 35 controls and peritoneal fluid samples obtained from 53 women with endometriosis and 34 controls. Women from whom peritoneal fluid was collected represent the subgroup of patients from whom plasma was collected. All women completed a World Endometriosis Research Foundation clinical questionnaire and signed an informed consent form to participate in the study. The Bioethics Committee operating at the Medical University of Warsaw approved the collection of the material in accordance with opinion No. KB 223/2017, issued on December 12, 2017. Diagnostic laparoscopy was performed in all patients by trained gynaecologists. After surgery, each woman diagnosed with endometriosis was assigned an appropriate stage of disease advancement according to the revised American Fertility Society (rAFS) classification.

Sample Preparation:

Sampleprep ID:SP004127
Sampleprep Summary:Before analysis, all plasma and peritoneal fluid samples were thawed on ice, centrifuged at 2 750 g, 4°C for 5 min, and then vortexed for 15 min at 1200 RPM as advised by AbsoluteIDQ p180 kit instruction. AbsoluteIDQ p180 kit procedure started with the preparation of derivatization mixture, extraction, and FIA solvents. 10 µl of internal standard (IS) was put onto each 96-well plate. Afterward, 10 µl of the respective sample was pipetted into the previously assigned well. The plate was dried under a nitrogen stream using a Positive Pressure-96 Processor (Waters) for 30 min. At the end of the drying process, 50 µl of derivatization mix was added to each well and left to derivatize for 25 min at room temperature. The plate was further dried using a positive pressure manifold for 60 min. 300 µl of extraction solvent was added to each well, left to vortex at 450 RPM for 30 min, and then centrifuged at 500 g for 2 min to elute the extracted metabolites. 150 µl of eluted sample was transferred to a 96-well LC plate, diluted with 150 µl of pure water, and 10 µl of eluted sample was transferred to a 96-well FIA plate and diluted with 490 µl of FIA solvent. Before injection, plates were vortexed at 600 RPM for 5 and 10 min, respectively.
Sampleprep Protocol Filename:Endometriosis_methods.pdf

Chromatography:

Chromatography ID:CH004979
Chromatography Summary:Liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis was performed using Waters Acquity Ultra Performance Liquid Chromatography coupled with Waters TQ-S triple-quadrupole mass spectrometer.
Instrument Name:Waters Acquity
Column Name:Waters ACQUITY UPLC BEH C18 (50 x 2.1mm,1.7um) with Waters BEH C18 guard column (5 x 2.1mm, 1.7um)
Column Temperature:50
Flow Gradient:total time 6.0 min, values ​​in brackets are time points: 0% B (0.25 min) ->12% B (1.5 min) ->17.5% B (2.7 min) ->50% B (4.0 min) ->0% B (4.5 min) ->0% B (6.0 min)
Flow Rate:total time 6.0 min, values ​​in brackets are time points: 0.8mL/min (4.5 min) > 1mL/min (4.7 min) > 1mL/min (5.1 min) > 0.8mL/min (5.8 min) > 0.8mL/min (6.0 min)
Solvent A:100% water; 0.2% formic acid
Solvent B:100% acetonitrile; 0.2% formic acid
Chromatography Type:Reversed phase
  
Chromatography ID:CH004980
Chromatography Summary:Flow injection analysis using tandem mass spectrometry (FIA-MS/MS) analysis was performed using Waters Acquity Ultra Performance Liquid Chromatography coupled with Waters TQ-S triple-quadrupole mass spectrometer. Solvent B: 290mL methanol; 1 ampule FIA mobile phase additive
Instrument Name:Waters Acquity
Column Name:No column
Column Temperature:-
Flow Gradient:100% B (0-2min)
Flow Rate:total time 2.0 min, values ​​in brackets are time points: 0.15mL/min (0.05min)> 0.03mL/min (0.06min)> 0.03mL/min (1.1min)> 0.2mL/min (1.5min)> 0.8mL/min (1.6min)>0.8mL/min (1.85min)> 0.15mL/min (1.95min)> 0.15mL/min (2.0min)
Solvent A:-
Solvent B:290mL methanol; 1 ampule (10 mL) FIA mobile phase additive
Chromatography Type:Flow induction analysis

Analysis:

Analysis ID:AN006560
Analysis Type:MS
Analysis Protocol File:Endometriosis_methods.pdf
Chromatography ID:CH004979
Num Factors:20
Num Metabolites:42
Units:ng/ml
  
Analysis ID:AN006561
Analysis Type:MS
Analysis Protocol File:Endometriosis_methods.pdf
Chromatography ID:CH004980
Num Factors:20
Num Metabolites:142
Units:ng/ml
  
Analysis ID:AN006562
Analysis Type:MS
Analysis Protocol File:Endometriosis_methods.pdf
Chromatography ID:CH004980
Num Factors:20
Num Metabolites:1
Units:ng/ml
  logo